Cormorant Asset Management, LP Cardiff Oncology, Inc. Transaction History

Cormorant Asset Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$5.01 - $7.58 $479,557 - $725,557	-95,720 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.65 - $10.04 $360,962 - $544,971	-54,280 Reduced 36.19%	95,720 $637,000
Q4 2020 Feb 16, 2021	SELL	$12.02 - $24.71 $300,500 - $617,750	-25,000 Reduced 14.29%	150,000 $2.7 Million
Q3 2020 Nov 16, 2020	BUY	$4.25 - $14.19 $743,750 - $2.48 Million	175,000 New	175,000 $2.48 Million

12.1M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $148M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.